flecainide has been researched along with Syncope in 21 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Syncope: A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study sought to compare the differences between procainamide and flecainide to stress the His-Purkinje system during electrophysiological study (EPS) in patients with syncope and bundle branch block (BBB)." | 7.91 | Flecainide Versus Procainamide in Electrophysiological Study in Patients With Syncope and Wide QRS Duration. ( Ferreira-Gonzalez, I; Francisco-Pasqual, J; García-Dorado, D; Martin-Sanchez, G; Moya-Mitjans, A; Oristrell, G; Perez-Rodon, J; Rivas-Gandara, N; Roca-Luque, I; Rodríguez-García, J; Santos-Ortega, A, 2019) |
| "In patients with false-negative responses to the provocative testing with flecainide, cardiac syncope predicts SCA, allowing a more extensive and individualized evaluation." | 7.88 | Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing. ( Avanzas, P; Calvo, D; Coto, E; García, D; Gómez, J; González-Vasserot, M; María de la Hera, J; Morís, C; Pablo Flórez, J; Pérez, D; Reguero, J; Rubín, J; Valverde, I, 2018) |
| "The flecainide test is widely used in Brugada syndrome." | 7.72 | Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003) |
| " We describe the case of a 62-year-old male with latent Brugada syndrome in whom the intravenous infusion of flecainide for paroxysmal atrial fibrillation caused ECG abnormalities similar to those of an acute septal myocardial infarction." | 7.72 | [Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct]. ( Carotenuto, F; Cirillo, R; D'Errico, L; di Palma, F; Fontana, D; Granato, L; Pagano, V; Sestri, C; Vitiello, N, 2003) |
| " This study assessed in 1,330 patients followed up for 292 +/- 393 days the predictive value for cardiovascular safety of a system by which patients were classified according to ventricular arrhythmias on entry, presence or absence of organic heart disease and drug dose for flecainide acetate." | 7.67 | Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. ( Anderson, JL; Gentzkow, GD; Morganroth, J, 1986) |
| "This study sought to compare the differences between procainamide and flecainide to stress the His-Purkinje system during electrophysiological study (EPS) in patients with syncope and bundle branch block (BBB)." | 3.91 | Flecainide Versus Procainamide in Electrophysiological Study in Patients With Syncope and Wide QRS Duration. ( Ferreira-Gonzalez, I; Francisco-Pasqual, J; García-Dorado, D; Martin-Sanchez, G; Moya-Mitjans, A; Oristrell, G; Perez-Rodon, J; Rivas-Gandara, N; Roca-Luque, I; Rodríguez-García, J; Santos-Ortega, A, 2019) |
| "In patients with false-negative responses to the provocative testing with flecainide, cardiac syncope predicts SCA, allowing a more extensive and individualized evaluation." | 3.88 | Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing. ( Avanzas, P; Calvo, D; Coto, E; García, D; Gómez, J; González-Vasserot, M; María de la Hera, J; Morís, C; Pablo Flórez, J; Pérez, D; Reguero, J; Rubín, J; Valverde, I, 2018) |
| "The flecainide test is widely used in Brugada syndrome." | 3.72 | Flecainide test in Brugada syndrome: a reproducible but risky tool. ( Ceriotti, C; Galimberti, P; Gasparini, M; Mantica, M; Napolitano, C; Priori, SG; Simonini, S, 2003) |
| " We describe the case of a 62-year-old male with latent Brugada syndrome in whom the intravenous infusion of flecainide for paroxysmal atrial fibrillation caused ECG abnormalities similar to those of an acute septal myocardial infarction." | 3.72 | [Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct]. ( Carotenuto, F; Cirillo, R; D'Errico, L; di Palma, F; Fontana, D; Granato, L; Pagano, V; Sestri, C; Vitiello, N, 2003) |
| " This study assessed in 1,330 patients followed up for 292 +/- 393 days the predictive value for cardiovascular safety of a system by which patients were classified according to ventricular arrhythmias on entry, presence or absence of organic heart disease and drug dose for flecainide acetate." | 3.67 | Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. ( Anderson, JL; Gentzkow, GD; Morganroth, J, 1986) |
| "This multicenter study suggests that oral flecainide therapy is an effective and safe means of suppressing VAs in patients with ATS with KCNJ2 mutations, though the U-wave amplitude remained unchanged by flecainide." | 2.80 | Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. ( Aiba, T; Anzai, T; Hayashi, H; Horie, M; Ishibashi, K; Ishihara, M; Kamakura, S; Kimura, H; Kusano, K; Miyamoto, K; Miyamoto, Y; Nakajima, I; Noda, T; Ogawa, H; Ohno, S; Okamura, H; Shimizu, W; Tanioka, Y; Tsuboi, I; Tsuchiya, T; Yasuda, S; Yasuoka, C; Yoshida, Y, 2015) |
| "The short QT syndrome is characterized by familial sudden death, short refractory periods, and inducible ventricular fibrillation." | 2.71 | Short QT Syndrome: a familial cause of sudden death. ( Bianchi, F; Borggrefe, M; Gaita, F; Giustetto, C; Grossi, S; Riccardi, R; Richiardi, E; Schimpf, R; Wolpert, C, 2003) |
| "Catecholaminergic polymorphic ventricular tachycardia was diagnosed with the aid of an implantable loop recorder." | 1.39 | A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia. ( Anastasakis, A; Kotsaka, X; Luria, D; Mantziari, L; Paraskevaidis, S; Styliadis, IH; Vassilikos, V, 2013) |
| "Syncope was abolished after successful radiofrequency catheter ablation of the AFL." | 1.31 | Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs. ( Azegami, K; Hiejima, K; Hirao, K; Horikawa, T; Kawabata, M; Motokawa, K; Suzuki, F; Suzuki, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Cheung, CC | 1 |
| Scheinman, M | 1 |
| Lee, BK | 1 |
| Luna-López, R | 1 |
| Datino, T | 1 |
| Espinosa, MÁ | 1 |
| Fernández-Avilés, F | 1 |
| Arenal, Á | 1 |
| Pablo Flórez, J | 1 |
| García, D | 1 |
| Valverde, I | 1 |
| Rubín, J | 1 |
| Pérez, D | 1 |
| González-Vasserot, M | 1 |
| Reguero, J | 1 |
| María de la Hera, J | 1 |
| Avanzas, P | 1 |
| Gómez, J | 1 |
| Coto, E | 1 |
| Morís, C | 1 |
| Calvo, D | 1 |
| El-Battrawy, I | 1 |
| Borggrefe, M | 2 |
| Lang, S | 1 |
| Zhou, X | 1 |
| Akin, I | 1 |
| Roca-Luque, I | 1 |
| Francisco-Pasqual, J | 1 |
| Oristrell, G | 1 |
| Rodríguez-García, J | 1 |
| Santos-Ortega, A | 1 |
| Martin-Sanchez, G | 1 |
| Rivas-Gandara, N | 1 |
| Perez-Rodon, J | 1 |
| Ferreira-Gonzalez, I | 1 |
| García-Dorado, D | 1 |
| Moya-Mitjans, A | 1 |
| Lokhandwala, Y | 1 |
| Kumar, B | 1 |
| Sato, A | 1 |
| Takano, T | 1 |
| Chinushi, M | 1 |
| Minamino, T | 1 |
| Mantziari, L | 1 |
| Vassilikos, V | 1 |
| Anastasakis, A | 1 |
| Kotsaka, X | 1 |
| Paraskevaidis, S | 1 |
| Styliadis, IH | 1 |
| Luria, D | 1 |
| Miyamoto, K | 1 |
| Aiba, T | 1 |
| Kimura, H | 1 |
| Hayashi, H | 2 |
| Ohno, S | 1 |
| Yasuoka, C | 1 |
| Tanioka, Y | 1 |
| Tsuchiya, T | 1 |
| Yoshida, Y | 1 |
| Tsuboi, I | 1 |
| Nakajima, I | 1 |
| Ishibashi, K | 1 |
| Okamura, H | 1 |
| Noda, T | 1 |
| Ishihara, M | 1 |
| Anzai, T | 1 |
| Yasuda, S | 1 |
| Miyamoto, Y | 1 |
| Kamakura, S | 1 |
| Kusano, K | 1 |
| Ogawa, H | 1 |
| Horie, M | 1 |
| Shimizu, W | 1 |
| Beinart, R | 1 |
| Michailidis, A | 1 |
| Gurevitz, OT | 1 |
| Glikson, M | 1 |
| Gasparini, M | 1 |
| Priori, SG | 1 |
| Mantica, M | 1 |
| Napolitano, C | 1 |
| Galimberti, P | 1 |
| Ceriotti, C | 1 |
| Simonini, S | 1 |
| Vitiello, N | 1 |
| Cirillo, R | 1 |
| Fontana, D | 1 |
| Granato, L | 1 |
| Sestri, C | 1 |
| Pagano, V | 1 |
| D'Errico, L | 1 |
| Carotenuto, F | 1 |
| di Palma, F | 1 |
| Gaita, F | 1 |
| Giustetto, C | 1 |
| Bianchi, F | 1 |
| Wolpert, C | 1 |
| Schimpf, R | 1 |
| Riccardi, R | 1 |
| Grossi, S | 1 |
| Richiardi, E | 1 |
| Haghjoo, M | 1 |
| Arya, A | 1 |
| Emkanjoo, Z | 1 |
| Sadr-Ameli, MA | 1 |
| Füessl, HS | 1 |
| Greenberg, HM | 1 |
| Dwyer, EM | 1 |
| Hochman, JS | 1 |
| Steinberg, JS | 1 |
| Echt, DS | 1 |
| Peters, RW | 1 |
| Itoh, E | 1 |
| Suzuki, K | 2 |
| Tanabe, Y | 1 |
| Kawabata, M | 1 |
| Hirao, K | 1 |
| Horikawa, T | 1 |
| Motokawa, K | 1 |
| Suzuki, F | 1 |
| Azegami, K | 1 |
| Hiejima, K | 1 |
| Borgeat, A | 1 |
| Grbic, M | 1 |
| Morganroth, J | 1 |
| Anderson, JL | 1 |
| Gentzkow, GD | 1 |
| Wehr, M | 1 |
| Noll, B | 1 |
| Krappe, J | 1 |
3 trials available for flecainide and Syncope
| Article | Year |
|---|---|
Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.
Topics: Administration, Oral; Adolescent; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; Electrocardiogra | 2015 |
Short QT Syndrome: a familial cause of sudden death.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Ch | 2003 |
Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Databases, Factual; Death, Sudden, Cardiac; Drug Interactio | 1995 |
18 other studies available for flecainide and Syncope
| Article | Year |
|---|---|
A peculiar case of palpitations and syncope.
Topics: Andersen Syndrome; Arrhythmias, Cardiac; Flecainide; Humans; Mutation; Syncope | 2022 |
Permanent atrioventricular block after flecainide testing.
Topics: Aged; Atrioventricular Block; Brugada Syndrome; Electrocardiography; Female; Flecainide; Humans; Pac | 2020 |
Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing.
Topics: Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; False Negative Reactions; Fema | 2018 |
Sodium channel blockers in Brugada syndrome.
Topics: Ajmaline; Brugada Syndrome; Flecainide; Humans; Sodium Channel Blockers; Syncope | 2018 |
Flecainide Versus Procainamide in Electrophysiological Study in Patients With Syncope and Wide QRS Duration.
Topics: Aged; Aged, 80 and over; Bundle-Branch Block; Electrocardiography; Electrophysiologic Techniques, Ca | 2019 |
Flecainide to Unmask Infranodal Disease: A Better Sieve?
Topics: Bundle-Branch Block; Flecainide; Humans; Procainamide; Syncope | 2019 |
Usefulness of the intravenous flecainide challenge test before oral flecainide treatment in a patient with Andersen-Tawil syndrome.
Topics: Administration, Intravenous; Administration, Oral; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; | 2019 |
A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Flecainide; Follow-Up Studi | 2013 |
Is flecainide dangerous in long QT-3 patients?
Topics: Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; Female; Flecainide; Humans; Long QT S | 2009 |
Flecainide test in Brugada syndrome: a reproducible but risky tool.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Death, Sudden, Cardiac; Electrocardi | 2003 |
[Infusion of flecainide in a patient with atrial fibrillation and latent Brugada's syndrome has determined modifications of the electrocardiogram similar to those of a septal myocardial infarct].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Death, Sudden, Cardiac; Echocardiography; Electrocardio | 2003 |
Clinical and electrophysiologic profile of Brugada syndrome in Iranian patients.
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Defibrillators, Implantable; Electric Stimulatio | 2005 |
[Reason for worry: syncope in the morning].
Topics: Anti-Arrhythmia Agents; Circadian Rhythm; Death, Sudden, Cardiac; Diagnosis, Differential; Electroca | 2005 |
A case of vasospastic angina presenting Brugada-type ECG abnormalities.
Topics: Acetylcholine; Aged; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiovascular Agents; Chest | 1999 |
Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Electrocardiography; Electrophysio | 2001 |
[Syncope in a 16-year-old young man during a football match].
Topics: Adolescent; Atrial Fibrillation; Flecainide; Humans; Male; Syncope; Wolff-Parkinson-White Syndrome | 1986 |
Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide.
Topics: Arrhythmias, Cardiac; Death, Sudden; Drug Administration Schedule; Flecainide; Heart Failure; Humans | 1986 |
Flecainide-induced aggravation of ventricular arrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Humans | 1985 |